JP2018532736A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532736A5
JP2018532736A5 JP2018519039A JP2018519039A JP2018532736A5 JP 2018532736 A5 JP2018532736 A5 JP 2018532736A5 JP 2018519039 A JP2018519039 A JP 2018519039A JP 2018519039 A JP2018519039 A JP 2018519039A JP 2018532736 A5 JP2018532736 A5 JP 2018532736A5
Authority
JP
Japan
Prior art keywords
neoepitope
matched
hla
patient
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018519039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018532736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056692 external-priority patent/WO2017066357A1/en
Publication of JP2018532736A publication Critical patent/JP2018532736A/ja
Publication of JP2018532736A5 publication Critical patent/JP2018532736A5/ja
Pending legal-status Critical Current

Links

JP2018519039A 2015-10-12 2016-10-12 チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法 Pending JP2018532736A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240494P 2015-10-12 2015-10-12
US62/240,494 2015-10-12
PCT/US2016/056692 WO2017066357A1 (en) 2015-10-12 2016-10-12 Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors

Publications (2)

Publication Number Publication Date
JP2018532736A JP2018532736A (ja) 2018-11-08
JP2018532736A5 true JP2018532736A5 (cg-RX-API-DMAC10.html) 2019-01-17

Family

ID=57882841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519039A Pending JP2018532736A (ja) 2015-10-12 2016-10-12 チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法

Country Status (10)

Country Link
US (2) US11626187B2 (cg-RX-API-DMAC10.html)
EP (1) EP3362930A4 (cg-RX-API-DMAC10.html)
JP (1) JP2018532736A (cg-RX-API-DMAC10.html)
KR (1) KR20180087244A (cg-RX-API-DMAC10.html)
CN (1) CN108701173A (cg-RX-API-DMAC10.html)
AU (1) AU2016339035A1 (cg-RX-API-DMAC10.html)
CA (1) CA3003251A1 (cg-RX-API-DMAC10.html)
HK (1) HK1258091A1 (cg-RX-API-DMAC10.html)
IL (1) IL258679A (cg-RX-API-DMAC10.html)
WO (1) WO2017066357A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
AU2016339035A1 (en) 2015-10-12 2018-05-10 Nantomics, Llc Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
CN108701172A (zh) 2016-02-12 2018-10-23 南托米克斯有限责任公司 高通量识别患者特异性新表位作为癌症免疫疗法的治疗靶点
AU2017315468B2 (en) 2016-08-25 2020-02-13 Nantomics, Llc Immunotherapy markers and uses therefor
BR112019018307A2 (pt) * 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
CN111373050A (zh) 2017-06-20 2020-07-03 生物辐射实验室股份有限公司 用于遗传不稳定性的数字扩增试验
WO2019031938A2 (ko) * 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
US20200385815A1 (en) * 2017-12-20 2020-12-10 Nantomics, Llc Using cfRNA for Diagnosing Minimal Residual Disease
JP2021521812A (ja) * 2018-04-25 2021-08-30 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. 免疫療法反応の改善予測バイオマーカーとしての腫瘍機能変異及びエピトープ負荷
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2020041561A1 (en) * 2018-08-23 2020-02-27 Nantcell, Inc. Assessing microsatellite instability by liquid biopsy
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
WO2020091944A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Genomic and immune infiltration differences between msi and mss gi tumors
CN110556164B (zh) * 2019-09-09 2023-02-07 深圳裕策生物科技有限公司 用于目标区域捕获测序检测msi的方法、装置和存储介质
CN110910957B (zh) * 2019-12-31 2023-06-27 求臻医学科技(浙江)有限公司 一种基于单肿瘤样本高通量测序微卫星不稳定性探测位点筛选方法
CN111785324B (zh) * 2020-07-02 2021-02-02 深圳市海普洛斯生物科技有限公司 一种微卫星不稳定分析方法及装置
CN112183557A (zh) * 2020-09-29 2021-01-05 山西医科大学 基于胃癌组织病理图像纹理特征的msi预测模型构建方法
CN114974420A (zh) * 2021-10-29 2022-08-30 无锡臻和生物科技有限公司 预测胃肠肿瘤免疫检查点抑制剂疗效的标志物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003207459A1 (en) 2002-01-03 2003-07-24 The Scripps Research Institute Cancer-associated epitope
PT1601450E (pt) 2003-03-10 2013-09-06 Expression Pathology Inc Preparação líquida de tecido a partir de amostras biológicas, de tecidos e de células tratados histopatologicamente
US8207315B2 (en) 2003-08-20 2012-06-26 The Cleveland Clinic Foundation Gene and protein associated with angiogenesis and endothelial cell-specific apoptosis
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
US7811993B2 (en) 2005-06-29 2010-10-12 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
US9646134B2 (en) 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
JP6034782B2 (ja) 2010-05-25 2016-11-30 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニアThe Regents Of The University Of California Bambam:ハイスループットシークエンシングデータの同時比較解析
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
AU2014337063A1 (en) 2013-10-18 2016-05-19 Adaptive Biotechnologies Corp. Predicting patient responsiveness to immune checkpoint inhibitors
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
SG11201605432RA (en) * 2014-01-02 2016-07-28 Sloan Kettering Inst Cancer Determinants of cancer response to immunotherapy
US20190099475A1 (en) 2015-04-08 2019-04-04 Nantomics, Llc Cancer neoepitopes
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
AU2016311444B2 (en) 2015-08-25 2019-02-07 Nantomics, Llc Systems and methods for high-accuracy variant calling
AU2016339035A1 (en) 2015-10-12 2018-05-10 Nantomics, Llc Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors

Similar Documents

Publication Publication Date Title
JP7851982B2 (ja) 癌のための個別化ワクチン
Bolton et al. Noncoding RNAs in prostate cancer: the long and the short of it
US20250299774A1 (en) Methods and systems for detecting insertions and deletions
TWI642786B (zh) 與癌症有關之基因或分子變異之檢測
JP2018510657A5 (cg-RX-API-DMAC10.html)
Espinosa‐Parrilla et al. Genetic association of gastric cancer with miRNA clusters including the cancer‐related genes MIR29, MIR25, MIR93 and MIR106: results from the EPIC‐EURGAST study
Murphy et al. Length variations within the Merle retrotransposon of canine PMEL: correlating genotype with phenotype
JP2019517781A5 (cg-RX-API-DMAC10.html)
Plieskatt et al. A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma
Guo et al. Exome sequencing identifies a COL14A1 mutation in a large Chinese pedigree with punctate palmoplantar keratoderma
JP2018532736A (ja) チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法
Omrane et al. Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer
JP2024528489A5 (cg-RX-API-DMAC10.html)
JP2012531210A5 (cg-RX-API-DMAC10.html)
Wang et al. Identification of two disease-causing genes TJP2 and GJB2 in a Chinese family with unconditional autosomal dominant nonsyndromic hereditary hearing impairment
JP2024512372A (ja) オフターゲットポリヌクレオチド配列決定データに基づく腫瘍の存在の検出
KR102238912B1 (ko) Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
Sakthianandeswaren et al. Fine mapping of Leishmania major susceptibility Locus lmr2 and evidence of a role for Fli1 in disease and wound healing
JP2014535050A5 (cg-RX-API-DMAC10.html)
EP2576816A4 (en) METHOD AND KIT FOR THE DISTINCTION BETWEEN BREAST CANCER AND A GOOD BREAST DISEASE
Gillespie et al. Genomic modifiers of natural killer cells, immune responsiveness and lymphoid tissue remodeling together increase host resistance to viral infection
de Deus et al. Influence of IL10 (G1082A) and TNFα (G308A) polymorphisms on the survival of pediatric patients with ALL
ES2618808T3 (es) Detección de la mutación braquispina
CN116981782A (zh) 基于脱靶多核苷酸测序数据检测肿瘤的存在
Tripathi et al. A preliminary sketch of horn cancer transcriptome in Indian zebu cattle